Unlock the future of bladder cancer care at AUA2025 in Las Vegas! Join expert faculty to explore the latest breakthroughs and stay ahead with cutting-edge insights and practical guidance for personalized patient care. Register now!
For more information and to register for this CME/CE symposium, please visit: PeerView.com/Bladder2025-Live.
Recent breakthroughs in bladder cancer treatment are transforming patient care across all disease stages. Innovation in the form of intravesical therapies for NMIBC has reshaped the treatment paradigm for early-stage disease, while use of perioperative immune checkpoint inhibitors, alone or with other agents, has improved outcomes in MIBC. Furthermore, patients with mUC have a variety of options, including immunotherapy, ADCs, and FGFR inhibitors. With several approvals across the treatment landscape and other agents in late-stage clinical trials, what do clinicians practicing in the community need to know to individualize care for their patients?
In a MasterClass & Practicum event from PeerView Live and the Bladder Cancer Advocacy Network, expert faculty will provide guidance on bringing scientific advances to patients with bladder cancer as they review the latest clinical data, guideline recommendations, and real-world applications of modern bladder cancer therapies. Important topics will include optimizing treatment selection, managing treatment-related AEs, and improving patient engagement through shared decision-making. Join the experts at AUA2025 in Las Vegas and prepare to bring precision medicine to your patients!
This CME/MOC/AAPA/IPCE activity is provided by PVI, PeerView Institute for Medical Education.
This activity has been developed in partnership with the Bladder Cancer Advocacy Network.
This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., Ferring Pharmaceuticals, Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC (which are both Johnson & Johnson companies).